Enurezisli erişkin hastalarda biofeedback tedavisinin etkinliği

Abstract

Amaç: Çalışmanın amacı; primer monosemptomatik enurezisli MsE erişkinlerde, biofeedback tedavisinin etkinliğini araştırmaktır. Gereç ve Yöntemler: Prospektif dizaynlı bu çalışmada, primer MsE’li erişkin hastalar çalışmaya dahil edildi. Nörojen mesaneli, gündüz işeme problemi olan, anatomik anomalisi olan ve enurezisle ilişkili başka hastalığı olan hastalar çalışmaya alınmadı. Kriterlere uyan 13 hastanın demografik verileri kaydedildi. Biofeedback öncesinde ve tedavinin bitiminden sonra 3. ayda, hastaların enurezis sıklıkları, üroflovmetri değerleri, rezidüel idrar miktarları PVR ve total mesane hacmi TMH işeme hacmi + PVR değerlendirildi. Biofeedback tedavinin başarısı, ayda bir kez veya daha az gece ıslatması olarak tanımlandı. Bulgular: Altı erkek ve yedi kadını içeren toplam 13 hastanın yaş ortalaması 29.2 ± 8.2 idi. Biofeedback tedavisi öncesinde aylık enurezis sıklığı 23.4 ± 5.9 iken, tedavi sonrasında 5.2 ± 8.9 olarak hesaplandı p=0.002 . Biofeedback tedavisi öncesi ve sonrasında; PVR, maksimum idrar akım hızı Qm ve ortalama akım hızı Qa açısından fark saptanmadı. Biofeedback tedavisi sonrası, TMH’nin 277.8 ml’den 329.9 ml’ye yükseldiği belirlendi p=0.001 . Sonuç: Primer MsE olan erişkin hastalarda biofeedback tedavisi, güvenli basit ve kolay uygulanabilen bir tedavi seçeneğidir. Mesane kapasitesini artırdığı saptanan bu tedavi, bu özel hasta grubu için önerilebilir.

Keywords

• Biofeedback,erişkin treatment,which was found to increase TBV,may be recommended for this special patient enurezis,mesane kapasitesi,monosemptomatik enurezis,üroflovmetri

Effectiveness of biofeedback therapy in adult patients with enuresis

Abstract

Objectives: To investigate the effectiveness of biofeedback therapy for adult patients with primary monosymptomatic enuresis MsE . Material and Methods: In this prospective design study, the adult patients with primary MsE were included in the study. Patients with neuropathic bladder, daytime voiding problems, anatomical pathology and enuresis-related other diseases were excluded from the study. The demographic data of 13 adult patients who meeting the criteria were recorded. The outcomes of enuresis frequency, uroflowmetry parameters, post-void residual urine PVR and total bladder volume TBV voided volume + PVR were evaluated before and at the end of the three month after biofeedback treatment. One or less enuretic night in a month was defined as the success of the biofeedback therapy. Results: Including 6 men and 7 women, the mean age of 13 patients was 29.2 ± 8.2 years. Before biofeedback therapy the incidence of enuresis was 23.4 ± 5.9 monthly , while after treatment this was calculated as 5.2 ± 8.9 p=0.002 . There was no significant difference found between before and after biofeedback therapy in terms of PVR, maximum flow rate Qm and average flow rate Qa . The mean TBV of patients increased from 277.8 ml to 329.9 ml after biofeedback treatment p=0.001 . Conclusion: Biofeedback therapy is a safe, simple and minimally invasive treatment modality in adult patients with primary MsE. This treatment, which was found to increase TBV, may be recommended for this special patient group

Keywords

• adult enuresis,biofeedback,bladder capacity,monosymptomatic enuresis,uroflowmetry

References

1. Austin PF, Bauer SB, Bower W, et al. The standardization of terminology of lower urinary tract function in children and adolescents: update report from the Standardization Committee of the International Children’s Continence So- ciety. J Urol 2014;191:1863-5.
2. Kang SH, Bae JH, Shim KS, et al. Extracorporeal magnetic innervation therapy in children with refractory mono- symptomatic nocturnal enuresis. Urology 2007;70:576-80.
3. Tekgul S, Riedmiller H, Gerharz E. European Association of Paediatric Urology guidelines on paediatric urology 2015; pp. 33-5.
4. Giggins OM, Persson UM, Caulfield B. Biofeedback in re- habilitation. J Neuroeng Rehabil 2013;10:1743-54.
5. Ebiloglu T, Ergin G, Irkilata HC, Kibar Y. The biofeedback treatment for non-monosymptomatic enuresis nocturna. Neurourol Urodyn 2016;35:58-61.
6. Pfister C, Dacher JN, Gaucher S, et al. The usefulness of a minimal urodynamic evaluation and pelvic floor biofeed- back in children with chronic voiding dysfunction. BJU Int 1999;84:1054-7.
7. Berry A, Rudick K, Richter M, Zderic S. Objective versus subjective outcome measures of biofeedback: what really matters? J Pediatr Urol 2014;10:620-6.
8. Greene G, Gregory AM, Fone D, White J. Childhood sleep- ing difficulties and depression in adulthood: the 1970 Brit- ish Cohort Study. J Sleep Res 2015;24:19-23.

9. Hamano S, Yamanishi T, Igarashi T, Ito H, Murakami S. Functional bladder capacity as predictor of response to desmopressin and retention control training in mono- symptomatic nocturnal enuresis. Eur Urol 2000;37:718-22.
10. Hoekx L, Vermandel A, Wyndaele JJ. Functional bladder capacity after bladder biofeedback predicts long-term out- come in children with nocturnal enuresis. Scand J Urol Nephrol 2003;37:120-3.
11. Kibar Y, Piskin M, Irkilata HC, et al. Management of ab- normal postvoid residual urine in children with dysfunc- tional voiding. Urology 2010;75:1472-5.